{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2010"],"condition":["Metastatic Colorectal Cancer","Colorectal cancer","Advanced Solid Tumors","Colorectal Neoplasms","Solid tumors"],"disease":["Metastatic Colorectal Cancer","Advanced Solid Tumors","Colorectal Cancer","Colorectal Neoplasms","Solid Tumors"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2097924"],"location":["United States"],"study_start_month":["8"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer","description":"The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and 5-fluorouracil in patients with advanced solid tumors.","dates":{"creation":"2010-08-15"},"accession":"2097924","cross_references":{"ClinicalTrials___gov":["NCT01238939"]}}